Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Prostatic Neoplasms 1Oligodendroglioma 1Melanoma 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lung Neoplasms 1Glioma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Cyclophosphamide 176Rituximab 164fludarabine phosphate 97Peripheral Blood Stem Cell Transplantation 95Filgrastim 73Etoposide 67Radiotherapy 63Mycophenolic Acid 62Whole-Body Irradiation 58Tacrolimus 49Melphalan 49Cyclosporine 49Busulfan 47Lenalidomide 45Antilymphocyte Serum 39Vincristine 37Prednisone 37Cytarabine 37fludarabine 35Methotrexate 33Carmustine 32obinutuzumab 31Doxorubicin 30Bendamustine Hydrochloride 30Methylprednisolone 27ibritumomab tiuxetan 25Cord Blood Stem Cell Transplantation 25sargramostim 24Bortezomib 24Granulocyte Colony-Stimulating Factor 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Follicular × varlilumab × Clear all
NCT02924038 2024-06-14

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

University of California, San Francisco

Phase 1 Terminated
14 enrolled 10 charts
CNSLymphoid

Astrocytoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡